Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Matthias Magoola"'
Publikováno v:
BioMedInformatics, Vol 4, Iss 2, Pp 1441-1456 (2024)
This article delves into the intersection of generative AI and digital twins within drug discovery, exploring their synergistic potential to revolutionize pharmaceutical research and development. Through various instances and examples, we illuminate
Externí odkaz:
https://doaj.org/article/d57e802938e942b494c0351935810ab3
Autor:
Sarfaraz K. Niazi, Matthias Magoola
Publikováno v:
Biologics, Vol 3, Iss 4, Pp 355-379 (2023)
Recombinant technology has been around for nearly three quarters of a century and has revolutionized protein therapy. However, the cost of developing recombinant therapeutic proteins and the manufacturing infrastructure keeps their cost unaffordable
Externí odkaz:
https://doaj.org/article/f346e5a73b1c4bf795faa2ac6bbd8f8a
Autor:
Sarfaraz K. Niazi, Matthias Magoola
Publikováno v:
Biologics, Vol 3, Iss 4, Pp 380-401 (2023)
Therapeutic proteins treat many acute and chronic diseases that were until recently considered untreatable. However, their high development cost keeps them out of reach of most patients around the world. One plausible solution to lower-cost manufactu
Externí odkaz:
https://doaj.org/article/af311884fd404045a0c42ebd42136025
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 12, p 6683 (2024)
Antibodies that can selectively remove rogue proteins in the brain are an obvious choice to treat neurodegenerative disorders (NDs), but after decades of efforts, only two antibodies to treat Alzheimer’s disease are approved, dozens are in the test
Externí odkaz:
https://doaj.org/article/e4a9c881faf54c6dba2612892d578363
Publikováno v:
Pharmaceuticals, Vol 17, Iss 6, p 741 (2024)
Alzheimer’s disease (AD) remains a significant challenge in the field of neurodegenerative disorders, even nearly a century after its discovery, due to the elusive nature of its causes. The development of drugs that target multiple aspects of the d
Externí odkaz:
https://doaj.org/article/323584d109584086b5836f13c6abf93a
Autor:
Sarfaraz K. Niazi, Matthias Magoola
Publikováno v:
Biomedicines, Vol 12, Iss 4, p 851 (2024)
The recent setbacks in the withdrawal and approval delays of antibody treatments of neurodegenerative disorders (NDs), attributed to their poor entry across the blood–brain barrier (BBB), emphasize the need to bring novel approaches to enhance the
Externí odkaz:
https://doaj.org/article/9baccaf56b0b4df29e2dbe56305f3548